These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37062240)

  • 1. Mechanism of an RBM-targeted rabbit monoclonal antibody 9H1 neutralizing SARS-CoV-2.
    Chu X; Ding X; Yang Y; Lu Y; Li T; Gao Y; Zheng L; Xiao H; Yang T; Cheng H; Huang H; Liu Y; Lou Y; Wu C; Chen Y; Yang H; Ji X; Guo H
    Biochem Biophys Res Commun; 2023 Jun; 660():43-49. PubMed ID: 37062240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD.
    Errico JM; Zhao H; Chen RE; Liu Z; Case JB; Ma M; Schmitz AJ; Rau MJ; Fitzpatrick JAJ; Shi PY; Diamond MS; Whelan SPJ; Ellebedy AH; Fremont DH
    Cell Rep; 2021 Oct; 37(4):109881. PubMed ID: 34655519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure and function analysis of a potent human neutralizing antibody CA521
    Song D; Wang W; Dong C; Ning Z; Liu X; Liu C; Du G; Sha C; Wang K; Lu J; Sun B; Zhao Y; Wang Q; Xu H; Li Y; Shen Z; Jiao J; Wang R; Tian J; Liu W; Wang L; Deng YQ; Dou C
    Commun Biol; 2021 Apr; 4(1):500. PubMed ID: 33893388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD.
    Wang X; Hu A; Chen X; Zhang Y; Yu F; Yue S; Li A; Zhang J; Pan Z; Yang Y; Lin Y; Gao L; Zhou J; Zhao J; Li F; Shi Y; Huang F; Yang X; Peng Y; Tu L; Zhang H; Zheng H; He J; Zhang H; Xu L; Huang Q; Zhu Y; Deng K; Ye L
    Signal Transduct Target Ther; 2022 Apr; 7(1):114. PubMed ID: 35383141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain.
    Wheatley AK; Pymm P; Esterbauer R; Dietrich MH; Lee WS; Drew D; Kelly HG; Chan LJ; Mordant FL; Black KA; Adair A; Tan HX; Juno JA; Wragg KM; Amarasena T; Lopez E; Selva KJ; Haycroft ER; Cooney JP; Venugopal H; Tan LL; O Neill MT; Allison CC; Cromer D; Davenport MP; Bowen RA; Chung AW; Pellegrini M; Liddament MT; Glukhova A; Subbarao K; Kent SJ; Tham WH
    Cell Rep; 2021 Oct; 37(2):109822. PubMed ID: 34610292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination.
    Chen Y; Zhu L; Huang W; Tong X; Wu H; Tao Y; Tong B; Huang H; Chen J; Zhao X; Lou Y; Wu C
    Emerg Microbes Infect; 2021 Dec; 10(1):1390-1403. PubMed ID: 34120577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
    Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An
    Atanasoff KE; Brambilla L; Adelsberg DC; Kowdle S; Stevens CS; Hung CT; Fu Y; Lim R; Tran L; Allen R; Andrew Duty J; Bajic G; Lee B; Tortorella D
    bioRxiv; 2023 Apr; ():. PubMed ID: 37131698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
    Hussain A; Hasan A; Nejadi Babadaei MM; Bloukh SH; Chowdhury MEH; Sharifi M; Haghighat S; Falahati M
    Biomed Pharmacother; 2020 Oct; 130():110559. PubMed ID: 32768882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
    Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants.
    Kim JW; Heo K; Kim HJ; Yoo Y; Cho HS; Jang HJ; Lee HY; Ko IY; Woo JR; Cho YB; Lee JH; Yang HR; Shin HG; Choi HL; Hwang K; Kim S; Kim H; Chun K; Lee S
    Antiviral Res; 2023 Apr; 212():105576. PubMed ID: 36870394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.